-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 2021 Suzhou Hematology Summit, co-sponsored by the National Clinical Medical Research Center for Hematological Diseases, the First Affiliated Hospital of Soochow University and the Jiangsu Institute of Hematology, will be held in Suzhou on October 8-10, 2021
.
Since its inception in 2008, the Suzhou Hematology Summit has been successfully held for 13 sessions so far, sharing the progress of academic prefaces with many colleagues in hematology and well-known scholars in the field of hematology across the country.
It has become an important event in the field of hematology in China
.
This meeting invited several leading experts in the department of hematology, including Professor Wu Depei from the First Affiliated Hospital of Soochow University, Professor Xiao Zhijian from the Hematology Hospital of the Chinese Academy of Medical Sciences, Professor Huang Xiaojun from Peking University People’s Hospital, and Professor Ma Jun from Harbin Institute of Hematology and Tumor.
The cutting-edge progress was shared.
The topics covered multiple topics such as precision medicine, leukemia, lymphoma, myeloma, and red blood cell diseases.
Many experts shared the diagnosis and treatment of related difficult cases at the same time, which provided practical information for online and offline participants.
Clinical diagnosis and treatment ideas
.
On the afternoon of October 9th, the multi-center research sub-venue of the Suzhou Hematology Summit successfully held the launching ceremony of the China Systemic Mastocytosis (SM) Multi-center Collaborative Group and the first SM academic conference.
The first batch of participants participated in SM China.
The members of the multi-center collaboration group are composed of clinical hematology experts from more than 60 top blood centers across the country
.
Professor Wu Depei and Professor Xiao Zhijian first delivered speeches on the launch of China's SM multi-center collaboration group and the launch of the SM academic conference
.
Professor Li Zhixiong from the Hannover Medical School in Germany described the current status of SM diagnosis and treatment in Europe and the United States and put forward specific work suggestions for the SM multi-center collaboration group in China
.
Professor Jiang Qian from the Department of Hematology, Peking University People's Hospital, highly affirmed the establishment of the China SM multi-center collaboration group
.
Professor Chen Suning introduced the preparation work of the China SM Multi-Center Collaboration Group
.
The launching ceremony also invited the families of SM patients to share their path of diagnosis and treatment and their mental journey
.
Professor Chen Suning gave a speech on the topic of "SM Diagnosis and Treatment Thinking"
.
SM is a rare disease with very heterogeneous clinical manifestations, including skin itching, skin flushing, nausea, vomiting, diarrhea, dizziness, palpitations, memory/cognitive difficulties, depression, fatigue, arthralgia, myalgia, allergies, etc.
.
Excessive proliferation and activation of abnormal mast cells can cause extensive damage to multiple organ systems in patients with SM
.
Professor Chen Suning said that the difficulty in diagnosis and treatment of SM lies in the difficulty of identification.
SM patients often go to different departments, the median diagnosis time is prolonged, and the misdiagnosis rate is extremely high.
Therefore, it is difficult for repeated unexplained allergic reactions, edema, osteoporosis, Gastrointestinal ulcers or chronic abdominal cramps, etc.
, should be highly suspected of the existence of SM
.
Prof.
Shi Hongxia, Prof.
Xue Song, Prof.
Qu Shiqiang, Prof.
Deng Xiuzhi, Prof.
Yu Jie, and Prof.
Shi Xue subsequently shared SM cases and discussed the diagnosis and treatment of SM
.
Then the diagnosis experts from the First Affiliated Hospital of Soochow University: Liu Dandan, Zhu Mingqing, Cen Jiannong, Shen Hongjie, Wang Qian, Yin Jia and others gave speeches on the topic of "SM Diagnostic Platform", and how to pass the patient's bone marrow morphology, bone marrow pathology, flow cytometry Cytology, molecular diagnosis, gene sequencing, and serum trypsin detection to effectively diagnose SM were introduced in detail
.
Professor Chen Suning then introduced the SM diagnosis and treatment guidelines
.
Professor Chen Suning said that the current effective treatments for SM are very limited
.
Advanced SM includes aggressive SM (ASM), systemic mastocytosis with hematology-related tumors (SM-AHN) and mast cell leukemia (MCL).
Among them, the median overall survival (OS) of patients with ASM is approximately At 3.
5 years, the median OS of SM-AHN patients was about 2 years, while the median OS of MCL patients was less than half a year, and the prognosis was poor.
Even if a variety of symptomatic treatments were taken, allergic reactions, maculopapular rash, itching, diarrhea, Symptoms such as fatigue and bone pain continue to exist, resulting in limited work and daily life of patients, facing dual physical and mental pressures, and new treatment options are urgently needed
.
Professor Yang Xiaofei introduced the SM clinical research project and looked forward to the application prospects of SM related treatment methods
.
Prof.
Xinxin Cao then shared the latest progress of Avapritinib in SM
.
Avatinib is a highly selective KIT kinase inhibitor that can effectively inhibit the kinase activity of KIT D816V mutation
.
On June 17, 2021, Avatinib was approved by the US FDA for the treatment of advanced SM in adults
.
Based on the two clinical studies approved this time, it is shown that avatinib can significantly reduce the load of mast cells, induce sustained remission, and the depth of remission deepens over time; the overall survival (OS) of patients with advanced SM is relative to historical data Significantly extended
.
As the first approved therapy for advanced SM to target the KIT D816V mutation, avatinib is a milestone in the treatment of advanced SM, bringing significant clinical benefits to patients with advanced SM, and is expected to improve this The precise treatment of diseases will benefit more SM patients
.
Finally, the launching ceremony of the China SM multi-center collaboration group and the first China SM academic conference ended successfully in the heated discussion of the guests
.
Poke "read the original text", we make progress together
.
Since its inception in 2008, the Suzhou Hematology Summit has been successfully held for 13 sessions so far, sharing the progress of academic prefaces with many colleagues in hematology and well-known scholars in the field of hematology across the country.
It has become an important event in the field of hematology in China
.
This meeting invited several leading experts in the department of hematology, including Professor Wu Depei from the First Affiliated Hospital of Soochow University, Professor Xiao Zhijian from the Hematology Hospital of the Chinese Academy of Medical Sciences, Professor Huang Xiaojun from Peking University People’s Hospital, and Professor Ma Jun from Harbin Institute of Hematology and Tumor.
The cutting-edge progress was shared.
The topics covered multiple topics such as precision medicine, leukemia, lymphoma, myeloma, and red blood cell diseases.
Many experts shared the diagnosis and treatment of related difficult cases at the same time, which provided practical information for online and offline participants.
Clinical diagnosis and treatment ideas
.
On the afternoon of October 9th, the multi-center research sub-venue of the Suzhou Hematology Summit successfully held the launching ceremony of the China Systemic Mastocytosis (SM) Multi-center Collaborative Group and the first SM academic conference.
The first batch of participants participated in SM China.
The members of the multi-center collaboration group are composed of clinical hematology experts from more than 60 top blood centers across the country
.
Professor Wu Depei and Professor Xiao Zhijian first delivered speeches on the launch of China's SM multi-center collaboration group and the launch of the SM academic conference
.
Professor Li Zhixiong from the Hannover Medical School in Germany described the current status of SM diagnosis and treatment in Europe and the United States and put forward specific work suggestions for the SM multi-center collaboration group in China
.
Professor Jiang Qian from the Department of Hematology, Peking University People's Hospital, highly affirmed the establishment of the China SM multi-center collaboration group
.
Professor Chen Suning introduced the preparation work of the China SM Multi-Center Collaboration Group
.
The launching ceremony also invited the families of SM patients to share their path of diagnosis and treatment and their mental journey
.
Professor Chen Suning gave a speech on the topic of "SM Diagnosis and Treatment Thinking"
.
SM is a rare disease with very heterogeneous clinical manifestations, including skin itching, skin flushing, nausea, vomiting, diarrhea, dizziness, palpitations, memory/cognitive difficulties, depression, fatigue, arthralgia, myalgia, allergies, etc.
.
Excessive proliferation and activation of abnormal mast cells can cause extensive damage to multiple organ systems in patients with SM
.
Professor Chen Suning said that the difficulty in diagnosis and treatment of SM lies in the difficulty of identification.
SM patients often go to different departments, the median diagnosis time is prolonged, and the misdiagnosis rate is extremely high.
Therefore, it is difficult for repeated unexplained allergic reactions, edema, osteoporosis, Gastrointestinal ulcers or chronic abdominal cramps, etc.
, should be highly suspected of the existence of SM
.
Prof.
Shi Hongxia, Prof.
Xue Song, Prof.
Qu Shiqiang, Prof.
Deng Xiuzhi, Prof.
Yu Jie, and Prof.
Shi Xue subsequently shared SM cases and discussed the diagnosis and treatment of SM
.
Then the diagnosis experts from the First Affiliated Hospital of Soochow University: Liu Dandan, Zhu Mingqing, Cen Jiannong, Shen Hongjie, Wang Qian, Yin Jia and others gave speeches on the topic of "SM Diagnostic Platform", and how to pass the patient's bone marrow morphology, bone marrow pathology, flow cytometry Cytology, molecular diagnosis, gene sequencing, and serum trypsin detection to effectively diagnose SM were introduced in detail
.
Professor Chen Suning then introduced the SM diagnosis and treatment guidelines
.
Professor Chen Suning said that the current effective treatments for SM are very limited
.
Advanced SM includes aggressive SM (ASM), systemic mastocytosis with hematology-related tumors (SM-AHN) and mast cell leukemia (MCL).
Among them, the median overall survival (OS) of patients with ASM is approximately At 3.
5 years, the median OS of SM-AHN patients was about 2 years, while the median OS of MCL patients was less than half a year, and the prognosis was poor.
Even if a variety of symptomatic treatments were taken, allergic reactions, maculopapular rash, itching, diarrhea, Symptoms such as fatigue and bone pain continue to exist, resulting in limited work and daily life of patients, facing dual physical and mental pressures, and new treatment options are urgently needed
.
Professor Yang Xiaofei introduced the SM clinical research project and looked forward to the application prospects of SM related treatment methods
.
Prof.
Xinxin Cao then shared the latest progress of Avapritinib in SM
.
Avatinib is a highly selective KIT kinase inhibitor that can effectively inhibit the kinase activity of KIT D816V mutation
.
On June 17, 2021, Avatinib was approved by the US FDA for the treatment of advanced SM in adults
.
Based on the two clinical studies approved this time, it is shown that avatinib can significantly reduce the load of mast cells, induce sustained remission, and the depth of remission deepens over time; the overall survival (OS) of patients with advanced SM is relative to historical data Significantly extended
.
As the first approved therapy for advanced SM to target the KIT D816V mutation, avatinib is a milestone in the treatment of advanced SM, bringing significant clinical benefits to patients with advanced SM, and is expected to improve this The precise treatment of diseases will benefit more SM patients
.
Finally, the launching ceremony of the China SM multi-center collaboration group and the first China SM academic conference ended successfully in the heated discussion of the guests
.
Poke "read the original text", we make progress together
